Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

Author's Avatar
Nov 12, 2021
  • Company advancing XCARTTM pre-clinical development plan toward IND-enabling studies
  • Strengthened cash position to fund operations through XCART IND filing with recently completed $12.5 million private placement
  • Continued royalty stream growth through license agreement with PolyXen® platform technology